Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2009 Earnings Results

Alnylam Pharmaceuticals Misses on EPS — Stock Down 4.43%

The earnings report indicates that Alnylam Pharmaceuticals is facing significant challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 4.43%, likely due to investor concerns about the lack of guidance and the company's current financial health. Without clear direction from management, investors may remain cautious moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.55	N/A	-88.36%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns over current market conditions. They highlighted the ongoing challenges in the industry but did not offer any specific plans for improvement.

Management did not provide specific guidance for future performance.

The company acknowledged challenges in achieving profitability.

Alnylam Pharmaceuticals Misses on EPS — Stock Down 4.43%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS — Stock Down 4.43%

Key numbers

Management commentary